Log in
Donate

Clinical Trial: ECOG-ACRIN E4512

ECOG-ACRIN E4512

Status: Closed

NCT#02201992

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

(See required screening study ALLIANCE A151216)

Eligible for screening study DCP 001

E4512 is closed to accrual, effective May 10, 2024.

E4512 all study-specified treatment is to be completed effective June 18, 2025. Testing, biospecimen collection long-term follow-up and data submissions continues.

View All Clinical Trials
The Montana Cancer Consortium (MCC) is an independent nonprofit organization whose mission is to bring state-of-the-art cancer care to Montana, Idaho and Wyoming through National Cancer Institute (NCI) sponsored clinical research.

Navigation

About Us

Contact Us

Copyright © Montana Cancer Consortium | All rights reserved